InvestorsHub Logo
Followers 30
Posts 1475
Boards Moderated 0
Alias Born 07/10/2013

Re: None

Thursday, 03/31/2022 5:28:47 AM

Thursday, March 31, 2022 5:28:47 AM

Post# of 44690
As of today the checkpoint inhibitor lung disease patent from Advita is granted (published B1 status) by SwissREG.

~ posted by IG, Y@h00 RLFTF finance conversations

https://www.swissreg.ch/srclient/loadPatDocPdf/A2245C34750A590F2A5A747143F5C2BE30A253F6

The granted Advita patent is THE NEWS OF TODAY!

Everything else was already known to a certain extent.

There are further indications that the dispute with $NRXP will not be settled until after the court hearing on the secondary lawsuits in June or thereafter.

Read RLFTF's comment. Status Quo - Mediation is apparently suspended - apparently both parties are waiting for the rulings in the counterclaim. The rulings will also clarify the status of the parties. I speculate that both parties have deliberately and in collusion suspended mediation pending resolution of the cross-complaint. RLFTF speaks of having hopes to resolve the dispute amicably. But is obviously pushing for a landmark judgment in the counterclaim first. NRX is apparently also waiting for this.

~ posted by AdVita, Y@h00 RLFTF finance conversations